...
首页> 外文期刊>Medicine. >PRISMA-Efficacy and Safety of Vedolizumab for Inflammatory Bowel Diseases A Systematic Review and Meta-Analysis of Randomized Controlled Trials
【24h】

PRISMA-Efficacy and Safety of Vedolizumab for Inflammatory Bowel Diseases A Systematic Review and Meta-Analysis of Randomized Controlled Trials

机译:维多珠单抗对炎症性肠病的PRISMA疗效和安全性随机对照试验的系统评价和荟萃分析

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Vedolizumab is an anti-inflammatory monoclonal antibody that exclusively targets the alpha 4 beta 7 integrin. We aimed to systematically review the efficacy and safety of vedolizumab for patients with inflammatory bowel diseases (IBDs).
机译:Vedolizumab是一种抗炎性单克隆抗体,专门针对α4beta 7整联蛋白。我们旨在系统地审查维多珠单抗对炎症性肠病(IBD)患者的疗效和安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号